Regulation of aromatase P450 expression by puerarin in endometrial cell line RL95-2.

OBJECTIVE To study the effects of puerarin on the aromatase P450 (P450(arom)) mRNA expression and the effects of low-dose puerarin on transcription factors of the P450(arom) gene (P II) 5'-flanking region. METHODS The effects of puerarin on the P450(arom) mRNA expression were determined by real-time polymerase chain reaction (RT-PCR). The 5'-flanking region was amplified by PCR using human genomic cDNA as a template. By means of the restriction sites and sequence confirmation, the PCR product was cloned into reporter vector. Series of sequential deletion reporter constructs were transiently transfected into RL95-2 cells which were treated with or without puerarin. Luciferase activity was measured by Dual-Luciferase Reporter Assay System and Luminoskan Ascent luminometer. Furthermore, by using web-based search program, the most possible cis-acting elements and transcription factors were evaluated. RESULTS The data demonstrated that low-dose puerarin treatment could decrease P450(arom) expression at mRNA level compared to dimethyl sulphoxide (DMSO) treatment (P<0.01), and puerarin (10(-7)mol/L) had a time-course effect on P450(arom) mRNA expression, which reached the bottom at 12h (P<0.01). Cells transfected with the -763/+8 bp constructs showed decrease in relative luciferase activity after puerarin (10(-7)mol/L) treatment compared to DMSO treatment (P<0.05), indicating an essential regulatory site between -763 bp and -543 bp responsible for the transcription suppression by puerarin. Furthermore, the most possible transcription factors, which turned out to be AP-1(c-jun/c-fos) at -410/-401 bp were also evaluated. The activity of exogenous AP-1 was reduced after 12 hours of puerarin treatment (P<0.05). The inhibition of c-jun mRNA also showed a time-course effect, which bottomed out at 12h in parallel with that of P450(arom) (P<0.01). The protein level of c-jun was also down-regulated by puerarin (10(-7)mol/L) treatment at 12h. CONCLUSION The suppression of P450(arom) expression and activity may be associated with the down-regulation of transcription factor AP-1/c-jun. This partially explains the mechanisms whereby puerarin treats endometriosis.

[1]  R. Casper,et al.  Aromatase Inhibitors in the Treatment of Severe Endometriosis , 2007, Obstetrics and gynecology.

[2]  Tadao Tanaka,et al.  Effect of Soy Isoflavones on Endometriosis: Interaction With Estrogen Receptor 2 Gene Polymorphism , 2007, Epidemiology.

[3]  S. Leung,et al.  Puerarin, an isoflavonoid derived from Radix puerariae, potentiates endothelium-independent relaxation via the cyclic AMP pathway in porcine coronary artery. , 2006, European journal of pharmacology.

[4]  P. Skałba,et al.  Expression of aromatase and 5-α-reductase genes in endometrial adenocarcinoma , 2006 .

[5]  S. Whitehead,et al.  Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  Jianwen Liu,et al.  Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. , 2006, The Journal of nutritional biochemistry.

[7]  K. Ruan,et al.  Prunella stica inhibits the proliferation but not the prostaglandin production of Ishikawa cells. , 2006, Life sciences.

[8]  A. Chan,et al.  Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. , 2006, Life sciences.

[9]  Y. Xiangliang,et al.  Puerarin protects rat pancreatic islets from damage by hydrogen peroxide , 2006 .

[10]  Yong-hong Sun,et al.  The study of anti-metabolic syndrome effect of puerarin in vitro. , 2005, Life sciences.

[11]  J. Bo,et al.  Protection by puerarin against MPP+-induced neurotoxicity in PC12 cells mediated by inhibiting mitochondrial dysfunction and caspase-3-like activation , 2005, Neuroscience Research.

[12]  S. Bulun,et al.  Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment , 2005, Pharmacological Reviews.

[13]  Z. Gu,et al.  Puerarin reduces increased c-fos, c-jun, and type IV collagen expression caused by high glucose in glomerular mesangial cells , 2005, Acta Pharmacologica Sinica.

[14]  Xiaoxiang Zheng,et al.  The Neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats. , 2005, Planta medica.

[15]  J. Toppari,et al.  In vitro effects of diethylstilbestrol, genistein, 4-tert-butylphenol, and 4-tert-octylphenol on steroidogenic activity of isolated immature rat ovarian follicles. , 2005, Toxicology and applied pharmacology.

[16]  M. van den Berg,et al.  Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  M. Wolters,et al.  Soy isoflavones – a therapy for menopausal symptoms? , 2004, Wiener Medizinische Wochenschrift.

[18]  S. Bulun,et al.  Aromatase and endometriosis. , 2004, Seminars in reproductive medicine.

[19]  Y. P. Chen,et al.  Quantitation of a Glyptapanteles indiensis polydnavirus gene expressed in parasitized host, Lymantria dispar, by real-time quantitative RT-PCR. , 2003, Journal of virological methods.

[20]  D. Overstreet,et al.  Herbal remedies for alcoholism: promises and possible pitfalls. , 2003, Alcoholism, clinical and experimental research.

[21]  Youhua Liu,et al.  Identification of the estrogen sensitive marker in human endometrial carcinoma RL95-2 cells , 1994, Molecular and Cellular Endocrinology.

[22]  B. Ranney.  Etiology, prevention, and inhibition of endometriosis. , 1980, Clinical obstetrics and gynecology.

[23]  L. Berstein,et al.  CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease. , 2005, Neoplasma.

[24]  P. Devroey,et al.  Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. , 2005, Reproductive Biomedicine Online.

[25]  K. Setchell,et al.  Behavioral effects of endocrine-disrupting substances: phytoestrogens. , 2004, ILAR journal.

[26]  P. Whitten,et al.  Neurobehavioral actions of coumestrol and related isoflavonoids in rodents. , 2002, Neurotoxicology and teratology.

[27]  S. Bulun,et al.  Aromatase expression in endometriosis. , 1996, The Journal of clinical endocrinology and metabolism.